Stocktoria
Silexion Therapeutics Corp SLXN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-17
Silexion Therapeutics Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $7.1M | $5.8M | $3.7M |
| Operating income | -$11.6M | -$12.6M | -$4.7M |
| Income tax | $3,000 | $10,000 | $32,000 |
| Net income | -$11.9M | -$16.5M | -$5.1M |
| EPS (diluted) | $8.96 | $394.94 | $44.23 |
| Operating cash flow | -$10.8M | -$8.4M | -$4.5M |
| Free cash flow | -$10.8M | -$8.4M | -$4.5M |
| Cash & equivalents | $6.0M | $1.2M | $4.6M |
| Total assets | $7.2M | $2.9M | $5.3M |
| Total liabilities | $4.6M | $6.9M | $2.3M |
| Shareholders' equity | $2.6M | -$4.0M | -$15.5M |
Source: SEC EDGAR filings · CIK 0002022416 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.